Both trandolapril and verapamil are effective and widely used antihypertensive agents. The aim of this study was to estimate the efficacy and tolerability of trandolapril/ verapamil (Tr/Ve) combination for blood pressure control and renoprotection. PubMed, EMBASE and Cochrane Library were searched for relevant studies. A meta-analysis of all randomized controlled trials (RCTs) meeting the criteria was performed. Twelve RCTs were ultimately included out of 62 studies. (3) Incidence of all-cause adverse events (AEs) was comparable between combination and monotherapy. The present meta-analysis indicates that Tr/Ve combination provides a superior blood pressure control and a favourable renoprotective effect without an increase of overall AEs than verapamil monotherapy. The combination also shows a slight advantage over trandolapril monotherapy by reducing DBP and albuminuria to a greater extent.
Introduction
Hypertension is a highly prevalent risk factor for cardiovascular disease, which may be responsible for one third of global death. 1 According to the Joint National Committee, prevalence of hypertension may be as much as 1 billion and B7.1 million deaths per year may be attributable to hypertension. 2 Pharmacological treatment of hypertension is effective and can prevent cardiovascular and renal complications. Currently, several classes such as thiazide diuretics, b-blockers, calcium channel blockers (CCBs), angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers are widely used. However, blood pressure cannot be controlled by monotherapy in more than two thirds of patients. Two or more antihypertensive agents are required. 2 In many hypertensive patients, combination therapy can also minimize dose-dependent side effects.
ACEIs and CCBs have several advantages when haemodynamic and biochemical profiles are concerned and these two drugs have renoprotective effects. An earlier analysis showed that CCBs lowered blood pressure and non-dihydropyridine CCBs caused a greater reduction in proteinuria compared with dihydropyridine CCBs. 3 ACEIs reduce proteinuria and slow the progression of renal damage. 1 The combination of the CCB, verapamil, and the long-acting lipophilic ACEI, trandolapril, may be a useful antihypertensive strategy. Several randomized controlled trials (RCTs), clinical trials and cohort studies have proven that the trandolapril/ verapamil (Tr/Ve) combination was more effective and better tolerated than monotherapy in the treatment of essential hypertension with or without nephropathy. However, the numbers of cases in these studies are often limited and different results exit among those studies. Therefore, we undertook a systematic review and meta-analysis of all relevant RCTs to evaluate the efficacy and tolerability of the Tr/Ve combination versus monotherapy.
Methods
We tried to include all RCTs that compared the antihypertensive, renoprotective efficacy and the safety of the Tr/Ve combination with monotherapy. The inclusion criteria and methods of the analysis were specified in advance and documented in a protocol.
Eligibility and inclusion criteria Types of studies. RCTs studying the efficacy and/or the safety of the Tr/Ve combination were considered eligible without language or publication year restrictions.
Types of participants. Patients with hypertension, with or without other diseases such as metabolic syndrome and chronic kidney diseases were thought eligible. The exclusion criteria included pregnancy or risk of pregnancy, myocardial infarction, congestive heart failure, coronary artery disease and acute or chronic hepatic disease.
Types of interventions. Trials comparing the Tr/Ve combination with trandolapril or verapamil monotherapy in the treatment of hypertension were considered eligible.
Types of outcome measures. The reductions from baseline to end point in clinic systolic blood pressure (SBP) and diastolic blood pressure (DBP) were as primary antihypertensive efficacy variables. Secondary efficacy variable was BP response rate (DBPp95 mm Hg and/or a reduction X10 mm Hg). The renoprotective efficacy variables were the reduction from baseline to end point in 24-h proteinuria and 24-h albuminuria. The tolerability of the combination was assessed by focusing on its overall rate of adverse events (AEs) compared with monotherapy. The incidences of two specific AEs, cough and constipation compared with trandolapril and verapamil, respectively, were also evaluated.
Information sources and search strategy Studies were identified by searching electronic databases including PubMed (Any Date), EMBASE (1980-present), Cochrane Library (Issue 3, 2009) and China's BioMedical Disc (CBM, 1978-present) . No language restriction was imposed. The last search was performed on 28 June 2009. The reference lists of original researches, reviews, letters to the editor and case reports were also scanned.
The search combined the term 'trandolapril', 'gopten', 'ordrik' with 'verapamil', 'cordilox', 'iproveratril', 'veraloc', 'verapamilum'. The trade name of the Tr/Ve combination Tarka was also searched.
Study selection
Two reviewers (ZZ, XFY) independently assessed the eligibility of each article and any disagreement was solved by discussion. This process was checked by another author (WL).
Data extraction process and data items
We predefined a spreadsheet (Microsoft Excel 2007) for data extraction, tested it with three randomly selected RCTs and revised it accordingly. One review author (ZZ) extracted data from included studies and a second author (XFY) checked the extracted data. Disagreements were resolved by discussion.
The following data were extracted from each included trial: (1) characteristics of the trial (including the authors, the year of publication, the design of the trial-like randomization, blind method, drop-out and follow-up, and method for statistical analysis); (2) characteristics of participants (including age, gender, stage and severity of hypertension, baseline SBP/DBP values and any confounding); (3) types of interventions (including type, dose and duration of the Tr/Ve combination or monotherapy) and (4) types of outcomes (including baseline SBP/DBP values, end point SBP/DBP values, the change from baseline in SBP and DBP, therapeutic response rate of BP, reduction in 24-h proteinuria and 24-h albuminuria, overall rate of AEs, incidence of cough and constipation). When data were displayed graphically, we deciphered them using Engauge Digitizer 4.1.
Assessment of risk of bias
Two reviewers (ZZ, XFY) independently determined the adequacy of randomization, allocation concealment, blind method, report of drop-outs and followups and appraised each included article according to an adjusted quality scoring system that was based on Jadad Scale. 4 The system included: (1) was the study described as randomized? (2 ¼ properly with detailed description of randomization, 1 ¼ randomized but detail not reported, 0 ¼ inappropriate randomization); (2) was allocation concealment used? (2 ¼ properly used, 1 ¼ unclear, 0 ¼ not used); (3) was the blind method used? (2 ¼ double-blind, 1 ¼ single-blind, 0 ¼ open-label) and (4) were dropout and follow-up described? (1 ¼ numbers and reasons described, 0 ¼ not described).
Summary measures and methods of analysis
Not all the outcomes were reported in each article, we performed separate meta-analysis for each comparison. We used a random effects model to combine the data if significant heterogeneity existed (Po0.1).
Relative risk (RR) was calculated for dichotomous outcomes and weighted mean difference (WMD) for continuous ones (standardized mean difference was used when different scales were used among trials). When the mean and s.d. of changes from baseline to end point were reported, we extracted them directly. When baseline and end point data were reported, we calculated mean BP reduction and s.d. in accordance with Cochrane Handbook for Systematic Reviews of Interventions (version 4.2.6). 5 The statistical analysis was carried out using Review Manager Version 5.0.20 (Cochrane Collaboration, Oxford, UK).
Additional analyses
To test the results of this meta-analysis, we assessed the impact of components by sensitivity analysis.
Results

Study selection
As was shown in the flow diagram (Figure 1 ), the search of PubMed, EMBASE, Cochrane Library and CBM provided a total of 62 articles. Of these, 38 studies were discarded because after reviewing the abstracts it appeared that these papers clearly did not meet the criteria. We obtained 24 full papers for detail evaluation. Twelve of them met the inclusion criteria and were included in this systematic review. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] No additional studies that met the criteria for inclusion were identified by checking the references of relevant papers. No unpublished relevant studies were obtained.
Study characteristics
We obtained 24 full papers from 62 potentially eligible studies for detail evaluation. Among them, 12 studies were included for the present metaanalysis with 4104 patients involved. All the articles were in English. There were 10 double-blind parallel studies, 1 open-label parallel study and 1 cross-over study. In one trial, 14 patients were randomly assigned to several doses of Tr/Ve combination, we chose 2/180 mg daily, as this dose was commonly used in other trials. In one trial, 8 data were displayed graphically, and we deciphered standard error using Engauge Digitizer 4.1. Characteristics of each included article are shown in Table 1 .
Risk of bias within studies
The scores of quality assessment are presented in Table 1 .
Antihypertensive and renoprotective efficacy Clinic BP reduction and BP response rate. Nine studies reported clinic SBP and DBP reduction. 24-h proteinuria and albuminuria. Reduction in proteinuria was reported in two studies 6, 10 and a greater fall was found in Tr/Ve combination against verapamil (Table 2) . A greater reduction in albuminuria could also be found in Tr/Ve combination versus monotherapy (either trandolapril or verapamil) according to two studies 6, 11 (Table 2) .
Tolerability
We assessed the all-cause AEs of each treatment group in any eligible article. The incidences of two Trandolapril/verapamil versus monotherapy Z Zou et al specific AEs, cough and constipation, which are common for an ACEI or CCB therapy, respectively, is analysed.
The incidence of overall AEs was comparable. No significant difference was found in Tr/Ve combination against monotherapy (Table 2) .
No difference was found in the incidence of cough and constipation: combination versus trandolapril (cough, RR: 0.83, 95% CI: 0.54-1.27, fixed effect model); combination versus verapamil (constipation, RR: 0.86, 95% CI: 0.39-1.86, fixed effect model).
Sensitivity analysis
Sensitivity analysis was performed to evaluate the effects of methodological characteristics on the analysis of clinic DBP reduction. Statistical difference in DBP reduction was found but a significant heterogeneity existed when the combination was compared with trandolapril (P ¼ 0.001, I
2 ¼ 68%). In one trial, 17 the sample size was very limited (n ¼ 20) and it got a score of 2 according to quality scoring system. We reanalysed the results after excluding this study and no significant heterogeneity was found (P ¼ 0. 19 
Discussion
Hypertension is a global problem, and the situation is getting worse because the world population is getting older and aging is an important factor for the development of hypertension. 18 As hypertension is a risk factor for the development and progression of chronic kidney disease and hypertension control rate is substantially low in patients with chronic kidney disease, appropriate therapy is in urgent need. Many choices of combinations exist; however, the efficacy and safety of those combinations remain to be evaluated. 19 We focused on two widely used antihypertensive drugs, trandolapril and verapamil. Each agent has a favourable antihypertensive effect. Our meta-analysis reveal that the Tr/Ve combination provides superior blood pressure control compared with verapamil monotherapy, as evidenced by a greater fall in clinic SBP, DBP, protenuria and albuminuria. The combination also reduces DBP and albuminuria to a greater extent than trandolapril. Although no greater increase with statistical difference in BP response rate was found in the combination regimen compared with monotherapy, the combination group had a numerically higher rate of BP responders than monotherapy in each article that reported BP response rate (Figure 4 ). In total, there was a higher rate in the combination group versus trando- ACE inhibitors and non-DHPCCBs reduce proteinuria by different mechanisms. Trandolapril inhibits the conversion of angiotensin I to angiotensin II, leading to a decrease in vasoconstriction. This renal vasodilation, particularly on the efferent arteriole, leads to a fall in intraglomerular capillary pressure. 20 Whereas verapamil, a non-DHPCCB, exerts Trandolapril/verapamil versus monotherapy Z Zou et al its pharmacological effect by blocking the calcium influx. This effect causes dilatation of peripheral vessels and decreases systemic vascular resistance and blood pressure. It can function by blunting the increase of mesangial matrix expansion to decrease proteinuria in animal model 21 and attenuate the increase in matrix protein synthesis induced by glycated albumin. 22 The difference between combination regimen and monotherapy may be partly explained by interaction of the two agents. Another possible explanation for the additive efficacy of the combination may be relevant to their effects on glomerular size selectivity. 6 At the same time, the Tr/Ve combination may decrease vascular cell adhesion molecule 1, which prevents leukocyte infiltration in the kidney and thus reduces albuminuria. This function of reducing tissue damage has been confirmed by Rubio-Guerra et al. 11 Renoprotective effects can also be explained by a greater reduction in blood pressure.
Our analysis shows that there is no difference in all-cause AEs between the combination and monotherapy. This differs from many RCTs, which report a lower incidence of AEs in the combination group. We also evaluated the incidence of two specific AEs, which are frequent to ACEIs and CCBs, respectively, cough and constipation. Data reported showed that the incidence of cough in combination group was not lowered compared with trandolapril. Moreover, no difference was found in combination group versus verapamil when constipation was concerned. Thus, we did not find a better tolerability in the combination group.
Strengths and limitations of this meta-analysis
This is the first meta-analysis focusing on the efficacy and tolerability of Tr/Ve combination. Earlier, an abstract of a meta-analysis was published about Tr/Ve combination including some RCTs and cohort studies, which were not the best evidences to inform clinical practice. 23 We contacted the author, and were told the abstract was the only publication. In this meta-analysis, we used a wide range of variables clinically relevant and evaluated the combination's renoprotective efficacy additionally. Most articles we included are high-quality studies according to adjusted Jadad scale.
One limitation of our meta-analysis is that ours was based on data extracted from studies of different Recommendations for future research First, although our meta-analysis and many RCTs show that the Tr/Ve combination is a good drug therapy approach to hypertension in terms of efficacy and tolerability, the lack of key comparative data such as mortality leads to the puzzlements of doctors and the public, well-designed RCTs with long duration are needed to verify its effectiveness further more. Second, the fall of proteinuria obtained still remains distant from an optimal control. Further studies are needed to assess which measures (other drugs, a low protein intake) should be added to solve this problem. Third, several trials demonstrated that the Tr/Ve combination had a favourable profile on glycaemic control compared with other combinations. 24, 25 This feature makes the combination a potential choice for type 2 diabetic hypertensive patients. More RCTs are needed to evaluate the efficacy of glycaemic control.
In conclusion, this meta-analysis shows that in hypertensive patients, especially those ones with chronic kidney disease, the combination of Tr/Ve provides a superior blood pressure control and a favourable renoprotective effect without an increase of overall AEs than verapamil monotherapy and combination also shows a slight advantage over trandolapril monotherapy by reducing DBP and albuminuria to a greater extent. Thereby, the optimal blood pressure control and specific renoprotective effects of the combination therapy should be taken into consideration in the treatment of hypertension.
